Sublethal spinal ketamine produces neuronal apoptosis in rat pups by Engelhardt, T et al.
may have received less narcotic than their younger counter-
parts—or that these patients take drugs that may play a role in
cancer recurrence, such as  blockers and statins.4
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In Reply:
We thank our colleagues for their interest regarding our recent
work.1 In response to their inquiries, recurrence in our studywas
defined as any (local or metastatic) detection of colon cancer
after primary resection. In the commonwealth ofVirginia, treat-
ing physicians are required by law to report the cancer status of
all patients. The University of Virginia Cancer Center, Char-
lottesville, tracks this data. Therefore, we are fortunate to have
access to long-term follow-up cancer recurrence data on a large
number of patients. However, we fully acknowledge that any
retrospective study, includingours, is limitedby (1) the accuracy
of the available medical records, which may include missing
data, and (2) difficulty controlling bias and confounding factors
that could influence cancer recurrence (e.g.,  and  blockers,
statins, nonsteroidal antiinflammatory drugs, cyclooxygenase
inhibitors).
We agree with Dr. Tiouririne that intraoperative use of
epidural analgesia (i.e., to supplement general anesthetics)
may have different effects on cancer recurrence than epidural
analgesia used only postoperatively. As Christopherson et al.2
note, a variety of factors influence cancer recurrence. For
example, cancer stage and grade are almost always the best
predictors of recurrence. Although our analysis corrected for
major factors, our statistical modeling was, of course, re-
stricted to the available data.
Both letters assert that our findings contradict those of
Christopherson et al.2 However, this interpretation of our
results is inaccurate; neither we nor Christopherson et al.2
found an overall (primary hypothesis) benefit of epidural
analgesia. Unplanned post hoc subgroup analyses—including
our observation that cancer recurrence was reduced in older
patients who received epidural analgesia—are notoriously
unreliable. Indeed, such analyses, when statistically signifi-
cant at 0.05, have only a 57% chance of being replicated in
an identical clinical trial.3
Although the idea that regional analgesia may reduce the
incidence of cancer recurrence is exciting, it remains a hy-
pothesis at this time—a question that can be answered only
with prospective randomized clinical trials. Fortunately, sev-
eral such studies are already in progress.
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Sublethal Spinal Ketamine Produces
Neuronal Apoptosis in Rat Pups
To the Editor:
Sir, we read with interest the article by Walker et al. and the
accompanying editorial view.1,2 Undoubtedly, subarachnoid
administration of large doses of ketamine produces neuronal
apoptosis in newborn rats, as was eloquently demonstrated
by this article. However, we would like to request further
clarification regarding the statement “3 and 10 mg/kg pro-
duced increasing initial sedation, and higher doses were le-
thal.” Unlike the corresponding article regarding the safety of
intrathecal morphine in rat pups in the same issue,3 no indi-
cation of calculated LD50 of intrathecal ketamine is given.
We are not suggesting that similar dose response curves need
to be constructed4,5 but would welcome the publication of
supporting data.
Rat pups were also exposed to smaller doses of intrathecal
ketamine (0.1–0.3 mg/kg); again, no data on analgesic ac-
tion or neuronal apoptosis are given. These doses (rather
than more than 3 mg/kg) are the comparative and relevant
equivalents commonly employed for caudal anesthesia.6
We have also some concerns regarding reporting of the
apoptosis data.1 First, the authors are assuming that the cells
they are staining with active caspase-3 are indeed neurons
without assessing the cell type. Second, the authors have
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failed to fully normalize the data in that they have just
counted the number of positive cells, be they Fluoro-Jade C
or caspase-3 positive, in each field of view. This method does
not take into account the number of cells present in the
section or the size of the section. One method is based on the
generation of a “wandering mean.” To generate these data,
the following procedure should be undertaken. Count the
number of events (caspase-3 positive or Fluoro-Jade C posi-
tive cells) and the total number of relevant cells in the first
microscopic field. This will give the first apoptosis score (A1
based onN1 cells). In the second field, the process is repeated
and running scores recorded to give a running mean (A2
based on N2 cells). This process is repeated to give multiple
running averages (A3, N3 . . . An, Nn). If these are plotted,
the mean will be seen to wander and eventually oscillate
about a mean value, and as N increases, this will become less.
This procedure can then define experimentally the number
of events to be assessed to produce a given quality of data.7
Intrathecal ketaminemay have amuch narrower intrathe-
cal therapeutic index compared with that of morphine.
However, local anesthetic agents have been shown to have
detrimental effects on neuronal apoptosis,8 and the right
balance between exposing vulnerable children to potential
harmful general or regional anesthetics is yet to be estab-
lished. Until then, we need to pay attention to the primary
cause of morbidity and mortality in children: hypoxia.9
Thomas Engelhardt, M.D., Ph.D.,* Morgan Blaylock,
Ph.D., Markus Weiss, M.D. *Royal Aberdeen Children’s
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In Reply:
We thank Drs. Engelhardt, Blaylock, and Weiss for their
comments on our article,1 and we are happy to clarify the
issues of ketamine dosing. Intrathecal ketamine (30 mg/kg)
produced irreversible sedation and respiratory depression in
P3 pups, and excitation and convulsions in P21 animals after
emergence from anesthesia that necessitated termination. As
a result, the same degree of dose escalation was not possible
with ketamine as withmorphine. Rather than indicating that
“sublethal doses” of ketamine are associated with apoptosis,
this emphasizes the narrower therapeutic window between
analgesia and dose-limiting side effects with ketamine.
The authors incorrectly stated that “no data on analgesic
action” were provided for 0.1–0.3 mg/kg intrathecal ket-
amine. Figure 1B clearly presents dose-response data for an-
tihyperalgesic effects of intrathecal ketamine in both P3 and
P21 pups.1 Because of ketamine’s mode of action, increases
in baseline sensory threshold (i.e., antinociceptive effects) are
not seen. The increased primary afferent input after injury
(i.e., carrageenan-induced hind paw inflammation) results in
activation ofN-methyl D-aspartate-mediated sensitization in
the spinal cord, and dose-dependent reversal of hyperalgesia
by ketamine can now be demonstrated. This pattern of re-
sponse is discussed and referenced under “Dose-dependent
effects” in our manuscript. Significant reversal of hyperalge-
sia was seen 30 min after intrathecal ketamine 3 mg/kg in P3
rats and 15 mg/kg in P21 rats. As we had shown that ket-
amine produced apoptosis within this analgesic dose range in
P3 pups, repeating the same experiments with subtherapeu-
tic doses would represent unnecessary use of animals and
resources.
Engelhardt et al. refer to doses that “are the comparative
and relevant equivalents commonly employed for caudal an-
esthesia.”We are surprised that the authors expect there to be
a direct correlation between the doses uesd in different spe-
cies, at different ages, and by different routes. Again, these
issues were covered in our discussion.1 Our rationale for
describing results in terms of a therapeutic index was to pro-
vide a ratio of toxic to functional doses that could facilitate
comparison of different drugs at different developmental
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The above Letter was sent to the author of the associated Editorial
View, who declined to respond to the Letter.—James C. Eisenach,
M.D., Editor-in-Chief.
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